APA (7th ed.) Citation

Guida, A., Bimbatti, D., Di Marco, A., Calabrese, M., Beuselinck, B., Ciccarese, C., . . . Bracarda, S. (2025). 2680eP Metastatic fumarate hydratase-deficient renal cell carcinoma (FHRCC): Outcome on first-line immune checkpoint inhibitor (ICI) combination: a multicenter retrospective study (FUMAHRE study). Annals of Oncology, 36, S1430. https://doi.org/10.1016/j.annonc.2025.08.3291

Chicago Style (17th ed.) Citation

Guida, A., et al. "2680eP Metastatic Fumarate Hydratase-deficient Renal Cell Carcinoma (FHRCC): Outcome on First-line Immune Checkpoint Inhibitor (ICI) Combination: A Multicenter Retrospective Study (FUMAHRE Study)." Annals of Oncology 36 (2025): S1430. https://doi.org/10.1016/j.annonc.2025.08.3291.

MLA (9th ed.) Citation

Guida, A., et al. "2680eP Metastatic Fumarate Hydratase-deficient Renal Cell Carcinoma (FHRCC): Outcome on First-line Immune Checkpoint Inhibitor (ICI) Combination: A Multicenter Retrospective Study (FUMAHRE Study)." Annals of Oncology, vol. 36, 2025, p. S1430, https://doi.org/10.1016/j.annonc.2025.08.3291.